Results 31 to 40 of about 5,422 (196)

Stimulation of Erythrocyte Cell Membrane Scrambling by Mitotane

open access: yesCellular Physiology and Biochemistry, 2014
Background: Mitotane (1,1-dichloro-2-[o-chlorophenyl]-2-[p-chlorophenyl]ethane), a cytostatic drug used for the treatment of adrenocortical carcinomas, is effective by triggering tumor cell apoptosis. In analogy to apoptosis of nucleated cells, eryptosis
Janin Jacobi   +7 more
doaj   +1 more source

GPER agonist G-1 decreases adrenocortical carcinoma (ACC) cell growth in vitro and in vivo [PDF]

open access: yes, 2015
We have previously demonstrated that estrogen receptor (ER) alpha (ESR1) increases proliferation of adrenocortical carcinoma (ACC) through both an estrogen-dependent and -independent (induced by IGF-II/IGF1R pathways) manner.
Amendola, Donatella   +16 more
core   +2 more sources

Aspectos clínicos e moleculares de tumor adrenocortical metacrônico pediátrico [PDF]

open access: yes, 2011
The occurrence of metachronous adrenocortical carcinoma has rarely been described. We report a case of a child with virilizing adrenocortical metachronous tumors that, despite several metastases, presented long-term survival (15 years).
ALENCAR, Guilherme Asmar   +8 more
core   +2 more sources

Adjuvant therapy in adrenocortical carcinoma: prognostic factors and treatment options

open access: yesEndocrine Oncology, 2023
Adrenocortical carcinoma (ACC) is a rare cancer with high recurrence rates and heterogeneous clinical behavior. The role of adjuvant therapy remains unclear because of the challenges in collecting high-quality data for a rare cancer.
Ruaa Al-Ward   +2 more
doaj   +1 more source

Synthesis of β‐ 3 H‐mitotane for use in a rapid assay for mitotane metabolism [PDF]

open access: yes, 1995
A 3 H + ‐release method has been developed for the assay of β‐hydroxylation of the adrenolytic drug mitotane. β‐ 3 H‐mitotane was synthesized by the reduction of 1‐(2‐chlorophenyl)‐1‐(4‐chlorophenyl)‐2,2,2‐trichloroethane by an aluminium‐Hg 2 Cl 2 ...
Counsell, Raymond E.   +5 more
core   +1 more source

Monitoring the response of canine hyperadrenocorticism to trilostane treatment by assessment of acute phase protein concentrations [PDF]

open access: yes, 2010
<b>Background</b>: Acute phase proteins (APPS) include haptoglobin (Hp), C-reactive protein (CRP) and serum amyloid A (SAA). Increased Hp concentrations may be induced by endogenous or exogenous glucocorticoids in dogs. <b>Objectives&
Angles   +36 more
core   +1 more source

Diabetes mellitus secondary to Cushing's disease [PDF]

open access: yes, 2018
Associated with important comorbidities that significantly reduce patients’ overall wellbeing and life expectancy, Cushing’s disease (CD) is the most common cause of endogenous hypercortisolism.
Barbot, Mattia   +2 more
core   +2 more sources

The impact of mitotane therapy on serum-free proteins in patients with adrenocortical carcinoma

open access: yesEndocrine Connections
Introduction: Adrenocortical carcinoma (ACC) is a rare malignancy of the adrenal cortex. Whilst surgery is the preferred treatment, adjunctive therapy with mitotane may be offered post-surgically to minimise the risk of recurrence or, in the absence of ...
Magdalena Lech   +12 more
doaj   +1 more source

Neurological adverse events of mitotane in adrenocortical carcinoma: results of a pilot study

open access: yesFrontiers in Oncology, 2023
IntroductionMitotane, the only drug approved by the Food and Drug Administration (FDA) for the treatment of adrenocortical carcinoma, is associated with several side effects including neurotoxicity. The aim of our study is to investigate the relationship
Marilda Mormando   +11 more
doaj   +1 more source

Outcome after resection of Adrenocortical Carcinoma liver metastases: a retrospective study [PDF]

open access: yes, 2017
Background: Metastatic Adrenocortical Carcinoma (ACC) is a rare malignancy with a poor 5-year-survival rate (
Christine Spitzweg   +11 more
core   +1 more source

Home - About - Disclaimer - Privacy